This resolution is a simple House expression of support for designating May 2025 as “National Brain Tumor Awareness Month.” It lists the human and scientific challenges posed by brain tumors, encourages public awareness activities, expresses support for patients and caregivers, and urges collaborative research efforts.
The measure is symbolic: it signals Congressional attention and gives advocates a formal platform to promote outreach and coordination. It does not create new federal programs or appropriate money; instead, its practical effect will depend on how advocacy groups, hospitals, researchers, and federal agencies respond during the designated month.
At a Glance
What It Does
The bill is an H.Res. that formally endorses May 2025 as National Brain Tumor Awareness Month and articulates five resolving statements encouraging awareness, support for patients and families, backing for efforts to develop better treatments, and urging collaborative research approaches.
Who It Affects
Direct audiences include patient advocacy organizations, medical researchers and clinical centers, and public health communicators who run outreach campaigns; federal research agencies and congressional offices are targeted as audiences for the resolution's message rather than as entities receiving new duties or funding.
Why It Matters
Awareness-month designations concentrate public messaging and can amplify fundraising, recruitment for clinical trials, and policy attention. For a field with entrenched scientific and clinical challenges, the resolution creates a low-cost lever for stakeholders to coordinate advocacy and public engagement.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The resolution has two parts: a set of explanatory clauses that summarize the scope and severity of brain tumors and five short "Resolved" clauses that set out the House’s stance. The explanatory clauses describe why brain tumors are distinctive—complex biology, a large number of tumor types, treatment challenges, and poor long-term outcomes—and they say there’s a need for more public awareness and research progress.
The operative language does not create legal obligations. Instead, the resolution: expresses support for labeling May 2025 as a month of national awareness; encourages increased public attention to the disease and to honoring those affected; supports efforts to develop better treatments and improve quality of life; offers a statement of solidarity with patients, families, and caregivers; and urges collaboration across the research community.Because this is a House resolution of support, it is a policy signal rather than a funding vehicle.
Its practical value lies in signaling congressional interest that advocacy organizations, research institutions, and federal agencies can use to coordinate outreach, focus fundraising, and highlight opportunities for research partnerships during the month. There is no new reporting, regulatory change, or appropriation embedded in the text, so any follow-on activity depends on voluntary action by stakeholders.
The Five Things You Need to Know
The bill designates May 2025 as National Brain Tumor Awareness Month and sets out five specific "Resolved" directives encouraging awareness, support for patients, research, and collaboration.
The preamble cites an estimated more than 93,000 new primary brain tumor diagnoses in 2025, including about 5,000 children.
The text states an estimated more than 1,000,000 Americans are living with a brain tumor and projects about 18,330 deaths from malignant brain tumors in 2025.
The bill notes the average 5-year survival rate after diagnosis of a primary malignant brain tumor is 35.7 percent and highlights that few treatments approved since the 1980s extend survival by more than two years on average.
Congressional procedure detail: the resolution was introduced as H.Res. 371 and referred to the House Committee on Energy and Commerce; it is an expression of support and does not itself appropriate funds or create enforceable regulatory duties.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Statement of facts and rationale
This section collects factual assertions the sponsors rely on: incidence and mortality estimates, survival data, the multiplicity of tumor types, and treatment challenges. These clauses frame the need for awareness and research and function solely as explanatory background rather than creating any obligations.
Designation of May 2025
This single-clause resolution formally endorses the designation of the month. The practical effect is symbolic recognition that stakeholders can cite in communications and events; it does not instruct any agency to take action or allocate resources.
Calls for public awareness and better treatments
Clause 2 encourages increased public awareness to honor those affected and to boost outreach. Clause 3 expresses support for efforts to develop better treatments and improve quality of life. Together these clauses place research and public education at the center of the message but stop short of prescribing funding mechanisms or research priorities.
Support for patients and push for collaboration
Clause 4 expresses solidarity with patients, families, and caregivers; Clause 5 urges collaborative research approaches. The collaboration language promotes coordination among researchers and institutions, but the resolution contains no enforcement mechanism, grant authority, or designated convening body to operationalize that collaboration.
Nonbinding statement with no appropriation or regulatory change
As a simple House resolution, the document has no force of law: it does not change statutes, create regulatory duties, or authorize federal spending. Any downstream impacts—public campaigns, agency messaging, or stakeholder convenings—depend on voluntary action by outside parties or separate legislative or appropriations steps.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients and caregivers: The resolution raises public attention and provides an official platform for advocacy and awareness activities that can reduce stigma and increase community support.
- Patient advocacy organizations and nonprofits: They gain a Congressional imprimatur to anchor fundraising, awareness campaigns, and outreach during May 2025.
- Academic and clinical researchers: Greater awareness can help with patient recruitment for clinical trials, partnership-building, and philanthropic support for translational research.
- Hospitals and treatment centers: Visibility during a designated month can drive earlier presentation and referrals, and support institution-led education and screening initiatives.
- Federal research communicators and public health offices: The resolution gives them a clear opportunity to align messaging and public education without new rulemaking.
Who Bears the Cost
- Advocacy organizations and nonprofits: Running awareness events, campaigns, and outreach requires staff time and money, and the resolution implicitly asks these groups to scale activity during May without offering federal funds.
- Federal agencies and congressional offices: They may expend staff resources to respond to constituent interest or to coordinate messaging during the month, even though no new budget authority is provided.
- Private donors and institutions: Increased campaigning can divert philanthropic dollars toward awareness and short-term programs rather than long-term basic research priorities.
- Research institutions and clinical centers: Expect operational costs if they host events or expand trial enrollment activities in response to the designation.
- Opportunity cost for policymakers: The symbolic focus may absorb legislative attention that could otherwise be used to pursue concrete funding or regulatory reforms.
Key Issues
The Core Tension
The central dilemma is symbolic recognition versus substantive change: the resolution aims to galvanize attention and coordination for a deadly, underfunded area of medicine, but it offers no funding, enforcement, or institutional mechanism to convert awareness into the long-term research investment and programmatic change that would be necessary to materially improve patient outcomes.
Two implementation puzzles stand out. First, the resolution conflates heightened awareness and progress in research without creating the mechanisms that link the two.
Awareness campaigns can increase public engagement and fundraising, but translating that into new clinical tools requires sustained funding, prioritized research agendas, and regulatory pathways that this text does not address.
Second, the resolution places responsibility for action on stakeholders who already carry the burden: nonprofits, clinical centers, and research institutions. Without a designated federal lead, funding commitment, or measurement plan, the month risks producing publicity spikes without durable change.
Finally, the bill cites stark epidemiological and survival figures to justify attention; those figures may sharpen advocacy but also raise ethical and practical questions about expectations—public messaging needs to balance hope with the reality that progress in brain tumor therapeutics has been slow and scientifically difficult.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.